In early 2019, Veristat helped Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. To date, this is one of the largest studies completed in Canada consisting of 360 patients with osteoarthritis (“OA”) of the knee, across 40 clinical sites.
Increasing Its Footprint and Expanding Therapeutic Expertise to Guide Sponsors Throughout the Clinical Development Lifecycle
Veristat Strengthens Its Regulatory Expertise with the Acquisition of Catalyst Regulatory Services
December 16, 2019
Expanding Its Team of Regulatory Experts to Guide Biopharmaceutical Sponsors
Along the Pathway to Market Approval
Veristat Expands Operations into Taiwan
July 23, 2019
Veristat Expands Operations into Taiwan to Support Growing Client Demand for Clinical Trial, Biostatistics and Programming Excellence in the Region
Opens office in Taipei, Taiwan
Veristat Advances Game-Changing Pain and Inflammation Therapy
January 24, 2019
Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, as they receive approval to initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346.
Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA Approvals
January 6, 2019
Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding
Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346. The study will run in Canada and is expected to conclude in December 2018.
Veristat Partners with TRI For Risk-Based Monitoring Technology
November 5, 2018
Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients
Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma
Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™
August 20, 2018
Continues Collaboration to Provide Regulatory Submission Support for
Additional Patisiran Submissions
SOUTHBOROUGH, MA – August 20, 2018 – Veristat, a full service Clinical Research Organization (CRO), congratulates Alnylam on the recent FDA approval of ONPATTRO™ (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.